These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 25167216)

  • 1. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
    Dennis G; Holweg CT; Kummerfeld SK; Choy DF; Setiadi AF; Hackney JA; Haverty PM; Gilbert H; Lin WY; Diehl L; Fischer S; Song A; Musselman D; Klearman M; Gabay C; Kavanaugh A; Endres J; Fox DA; Martin F; Townsend MJ
    Arthritis Res Ther; 2014; 16(2):R90. PubMed ID: 25167216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.
    Badot V; Galant C; Nzeusseu Toukap A; Theate I; Maudoux AL; Van den Eynde BJ; Durez P; Houssiau FA; Lauwerys BR
    Arthritis Res Ther; 2009; 11(2):R57. PubMed ID: 19389237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
    Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
    Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
    Humby F; Durez P; Buch MH; Lewis MJ; Rizvi H; Rivellese F; Nerviani A; Giorli G; Mahto A; Montecucco C; Lauwerys B; Ng N; Ho P; Bombardieri M; Romão VC; Verschueren P; Kelly S; Sainaghi PP; Gendi N; Dasgupta B; Cauli A; Reynolds P; Cañete JD; Moots R; Taylor PC; Edwards CJ; Isaacs J; Sasieni P; Choy E; Pitzalis C;
    Lancet; 2021 Jan; 397(10271):305-317. PubMed ID: 33485455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis.
    Orr C; Najm A; Biniecka M; McGarry T; Ng CT; Young F; Fearon U; Veale DJ
    Arthritis Rheumatol; 2017 Nov; 69(11):2114-2123. PubMed ID: 28732135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
    Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
    Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
    Astorri E; Nerviani A; Bombardieri M; Pitzalis C
    Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
    Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
    Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
    Front Immunol; 2019; 10():1459. PubMed ID: 31312201
    [No Abstract]   [Full Text] [Related]  

  • 11. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.
    Humby F; Lewis M; Ramamoorthi N; Hackney JA; Barnes MR; Bombardieri M; Setiadi AF; Kelly S; Bene F; DiCicco M; Riahi S; Rocher V; Ng N; Lazarou I; Hands R; van der Heijde D; Landewé RBM; van der Helm-van Mil A; Cauli A; McInnes I; Buckley CD; Choy EH; Taylor PC; Townsend MJ; Pitzalis C
    Ann Rheum Dis; 2019 Jun; 78(6):761-772. PubMed ID: 30878974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy.
    De Groof A; Ducreux J; Humby F; Nzeusseu Toukap A; Badot V; Pitzalis C; Houssiau FA; Durez P; Lauwerys BR
    Arthritis Res Ther; 2016 Jan; 18():19. PubMed ID: 26792343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
    Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
    Chen YC; Chiu WC; Su FM; Chen JF
    Int J Rheum Dis; 2018 Sep; 21(9):1695-1700. PubMed ID: 29024421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
    Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
    Rivellese F; Nerviani A; Giorli G; Warren L; Jaworska E; Bombardieri M; Lewis MJ; Humby F; Pratt AG; Filer A; Gendi N; Cauli A; Choy E; McInnes I; Durez P; Edwards CJ; Buch MH; Gremese E; Taylor PC; Ng N; Cañete JD; Raizada S; McKay ND; Jadon D; Sainaghi PP; Stratton R; Ehrenstein MR; Ho P; Pereira JP; Dasgupta B; Gorman C; Galloway J; Chinoy H; van der Heijde D; Sasieni P; Barton A; Pitzalis C;
    Lancet Rheumatol; 2023 Nov; 5(11):e648-e659. PubMed ID: 38251532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
    Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
    Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.